SCHEMBL5337806

SCHEMBL5337806

CCc1nccn1Cc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
ACHE P22303 2/20 0.46
PLA2G7 Q13093 1/20 0.44
MGLL Q99685 1/20 0.44
ABHD6 Q9BV23 1/20 0.44
GPR119 Q8TDV5 6/20 0.43
MC4R P32245 1/20 0.43
POLB P06746 1/20 0.43
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KMT2A Q03164 1/20 0.42
PDK2 Q15119 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332037 0.88 MC4R (0.54) OPRD1OPRK1CKS1BSKP1SKP2
SCHEMBL14387785 0.86 OPRD1 (0.46) OPRD1OPRK1CKS1BSKP1SKP2
SCHEMBL5337967 0.86 OPRD1 (0.47) OPRD1OPRK1CKS1BSKP1SKP2
SCHEMBL14387751 0.86 OPRD1 (0.47) OPRD1OPRK1CKS1BSKP1SKP2
SCHEMBL7981893 0.84 GAA (0.56) CKS1BSKP1SKP2ACHEGPR119
SCHEMBL7986047 0.82 CKS1B (0.57) CKS1BSKP1SKP2ACHEPLA2G7
SCHEMBL5343839 0.82 ACHE (0.48) OPRD1OPRK1CKS1BSKP1SKP2
SCHEMBL14355815 0.80 DRD2 (0.51) MC4RKMT2A
SCHEMBL5335315 0.79 MC4R (0.53) CKS1BSKP1SKP2ACHEPLA2G7
SCHEMBL5335100 0.78 PLA2G7 (0.61) CKS1BSKP1SKP2ACHEPLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R OPRD1 49/4885OPRK1 51/4885CKS1B 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.